{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:18:46Z","timestamp":1788826726412,"version":"build-2803163510"},"reference-count":10,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"DOI":"10.2340\/actadv.v105.43637","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T08:35:22Z","timestamp":1761640522000},"page":"adv43637","source":"Crossref","is-referenced-by-count":2,"title":["Combination of Omalizumab and Dupilumab for the Treatment of Severe Bullous Pemphigoid: a Series of 6 Cases"],"prefix":"10.2340","volume":"105","author":[{"given":"Romain","family":"Boisseau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Scaramuzzino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Bedane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salome","family":"Fourmond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2025,10,28]]},"reference":[{"key":"131255","doi-asserted-by":"crossref","unstructured":"Akbarialiabad H, Schmidt E, Patsatsi A, Lim YL, Mosam A, Tasanen K, et al. Bullous pemphigoid. Nat Rev Dis Primers 2025; 11: 12.","DOI":"10.1038\/s41572-025-00595-5"},{"key":"131256","doi-asserted-by":"crossref","unstructured":"Borradori L, Van Beek N, Feliciani C, Tedbirt B, Antiga E, Bergman R, et al. Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol 2022; 36: 1689\u20131704.","DOI":"10.1111\/jdv.18220"},{"key":"131257","doi-asserted-by":"crossref","unstructured":"Kridin K, Bergman R. Mortality in patients with bullous pemphigoid: a retrospective cohort study, systematic review and meta-analysis. Acta Derm Venereol 2019; 99: 72\u201377.","DOI":"10.2340\/00015555-2930"},{"key":"131258","doi-asserted-by":"crossref","unstructured":"Chebani R, Lombart F, Chaby G, Dadban A, Debarbieux S, Viguier MA, et al. Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a French national multicentre retrospective study of 100 patients. Br J Dermatol 2024; 190: 258\u2013265.","DOI":"10.1093\/bjd\/ljad369"},{"key":"131259","doi-asserted-by":"crossref","unstructured":"Karakioulaki M, Eyerich K, Patsatsi A. Advancements in bullous pemphigoid treatment: a comprehensive pipeline update. Am J Clin Dermatol 2024; 25: 195\u2013212.","DOI":"10.1007\/s40257-023-00832-1"},{"key":"131260","doi-asserted-by":"crossref","unstructured":"Vassallo C, Somenzi A, De Amici M, Barruscotti S, Brazzelli V. Omalizumab as a corticosteroid-sparing agent in the treatment of bullous pemphigoid. Dermatol Ther 2022; 35: e15946.","DOI":"10.1111\/dth.15946"},{"key":"131261","doi-asserted-by":"crossref","unstructured":"Harb H, Chatila TA. Mechanisms of dupilumab. Clin Exp Allergy 2020; 50: 5\u201314.","DOI":"10.1111\/cea.13491"},{"key":"131262","doi-asserted-by":"crossref","unstructured":"Zhao L, Wang Q, Liang G, Zhou Y, Yiu N, Yang B, et al. Evaluation of dupilumab in patients with bullous pemphigoid. JAMA Dermatol 2023; 159: 953\u2013960.","DOI":"10.1001\/jamadermatol.2023.2428"},{"key":"131263","doi-asserted-by":"crossref","unstructured":"Planella-Fontanillas N, Bosch-Amate X, Jim\u00e9nez Ant\u00f3n A, Moreno-V\u00edlchez C, Guerrero MG, Blanes Mart\u00ednez MDM, et al. Real-world evaluation of the effectiveness and safety of dupilumab in bullous pemphigoid: an ambispective multicentre case series. Br J Dermatol 2025; 192: 501\u2013509.","DOI":"10.1093\/bjd\/ljae403"},{"key":"131264","doi-asserted-by":"crossref","unstructured":"Seyed Jafari SM, Feldmeyer L, Bossart S, Simon D, Schlapbach C, Borradori L. Case Report: Combination of omalizumab and dupilumab for recalcitrant bullous pemphigoid. Front Immunol 2021; 11: 611549.","DOI":"10.3389\/fimmu.2020.611549"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/43637\/51863","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/43637\/51863","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T08:41:51Z","timestamp":1761640911000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/43637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,28]]},"references-count":10,"URL":"https:\/\/doi.org\/10.2340\/actadv.v105.43637","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,28]]}}}